旨在评估卵巢组织冷冻保存和自体冷冻卵巢组织移植在妇科癌症患者生育力保存中的实用性、成功性和安全性。对 MEDLINE、EMBASE、ClinicalTrials.gov 和 Cochrane 图书馆数据库进行了全面检索，以确定相关的从开始到2024年1月23日，对卵巢组织冷冻保存和自体冷冻卵巢组织移植治疗妇科癌症的效用和结果进行了研究。两名评审员独立进行了研究选择、数据提取和偏倚风险评估，结果为然后一起复习。当前的系统评价纳入了 23 项研究。对所得数据进行荟萃分析，以对卵巢组织冷冻保存和自体移植在妇科癌症中的效用（占所有适应症的比例）进行汇总效应估计。我们发现，接受卵巢组织冷冻保存和自体移植的女性分别有 7.5% 和 9.6% 患有妇科癌症。相比之下，血液系统恶性肿瘤和乳腺癌约占这些手术所有适应症的 66.0%。妇科癌症自体冷冻卵巢组织移植的回报率（6.0%）与其他适应症的回报率没有统计学差异。在接受卵巢刺激的妇科癌症女性中，27.3%的女性至少生育过一个孩子，自体移植后78.1%的女性卵巢内分泌功能恢复。中位移植物寿命为 32 个月，并且在妇科癌症女性自体移植后没有报道移植部位复发。我们的结果表明，卵巢组织冷冻保存和自体移植是保留妇科癌症女性卵巢功能的可行选择，尽管卵巢癌组织冷冻保存未得到充分利用，需要进一步研究来确定自体移植的长期结果。PROSPERO，CRD42024498522。版权所有 © 2024 美国妇产科学院。由 Wolters Kluwer Health, Inc. 出版。保留所有权利。

To evaluate the utility, success, and safety of ovarian tissue cryopreservation and autologous cryopreserved ovarian tissue transplantation for fertility preservation in patients with gynecologic cancers.A comprehensive search was performed of the MEDLINE, EMBASE, ClinicalTrials.gov, and Cochrane Library databases to identify relevant studies on the utility and outcomes of ovarian tissue cryopreservation and autologous cryopreserved ovarian tissue transplantation for gynecologic cancers from inception until January 23, 2024.Two reviewers independently performed the study selection, data extraction, and risk-of-bias assessment, and the results were then reviewed together. Twenty-three studies were included in the current systematic review.The resultant data were meta-analyzed to produce a pooled-effect estimate of the utility of ovarian tissue cryopreservation and autologous transplantation in gynecologic cancers as a proportion of all indications. We found that 7.5% and 9.6% of women undergoing ovarian tissue cryopreservation and autologous transplantation, respectively, had gynecologic cancers. In comparison, hematologic malignancies and breast cancer accounted for approximately 66.0% of all indications for these procedures. The return rate for autologous cryopreserved ovarian tissue transplantation in gynecologic cancers (6.0%) was not statistically different from those for other indications. Among women with gynecologic cancer who underwent ovarian stimulation, 27.3% had at least one child, and the ovarian endocrine function was restored in 78.1% of the women after autologous transplantation. The median graft longevity was 32 months, and no graft-site recurrence was reported after autologous transplantation in women with gynecologic cancer.Our results suggest that ovarian tissue cryopreservation and autologous transplantation are feasible options for preserving ovarian function in women with gynecologic cancers, although ovarian tissue cryopreservation is underutilized, and further studies are needed to determine the longer-term outcomes of autologous transplantation.PROSPERO, CRD42024498522.Copyright © 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.